OBJECTIVE: We wanted to prospectively assess the adverse events and hemodynamic effects associated with an intravenous adenosine infusion in patients with suspected or known coronary artery disease and who were undergoing cardiac MRI. MATERIALS AND METHODS: One hundred and sixty-eight patients (64 ± 9 years) received adenosine (140 µg/kg/min) during cardiac MRI. Before and during the administration, the heart rate, systemic blood pressure, and oxygen saturation were monitored using a MRI-compatible system. We documented any signs and symptoms of potential adverse events. RESULTS: In total, 47 out of 168 patients (28%) experienced adverse effects, which were mostly mild or moderate. In 13 patients (8%), the adenosine infusion was discontinued due to intolerable dyspnea or chest pain. No high grade atrioventricular block, bronchospasm or other life-threatening adverse events occurred. The hemodynamic measurements showed a significant increase in the heart rate during adenosine infusion (69.3 ± 11.7 versus 82.4 ± 13.0 beats/min, respectively; p < 0.001). A significant but clinically irrelevant increase in oxygen saturation occurred during adenosine infusion (96 ± 1.9% versus 97 ± 1.3%, respectively; p < 0.001). The blood pressure did not significantly change during adenosine infusion (systolic: 142.8 ± 24.0 versus 140.9 ± 25.7 mmHg; diastolic: 80.2 ± 12.5 mmHg versus 78.9 ± 15.6, respectively). CONCLUSION: This study confirms the safety of adenosine infusion during cardiac MRI. A considerable proportion of all patients will experience minor adverse effects and some patients will not tolerate adenosine infusion. However, all adverse events can be successfully managed by a radiologist. The increased heart rate during adenosine infusion highlights the need to individually adjust the settings according to the patient, e.g., the number of slices of myocardial perfusion imaging.
OBJECTIVE: We wanted to prospectively assess the adverse events and hemodynamic effects associated with an intravenous adenosine infusion in patients with suspected or known coronary artery disease and who were undergoing cardiac MRI. MATERIALS AND METHODS: One hundred and sixty-eight patients (64 ± 9 years) received adenosine (140 µg/kg/min) during cardiac MRI. Before and during the administration, the heart rate, systemic blood pressure, and oxygen saturation were monitored using a MRI-compatible system. We documented any signs and symptoms of potential adverse events. RESULTS: In total, 47 out of 168 patients (28%) experienced adverse effects, which were mostly mild or moderate. In 13 patients (8%), the adenosine infusion was discontinued due to intolerable dyspnea or chest pain. No high grade atrioventricular block, bronchospasm or other life-threatening adverse events occurred. The hemodynamic measurements showed a significant increase in the heart rate during adenosine infusion (69.3 ± 11.7 versus 82.4 ± 13.0 beats/min, respectively; p < 0.001). A significant but clinically irrelevant increase in oxygen saturation occurred during adenosine infusion (96 ± 1.9% versus 97 ± 1.3%, respectively; p < 0.001). The blood pressure did not significantly change during adenosine infusion (systolic: 142.8 ± 24.0 versus 140.9 ± 25.7 mmHg; diastolic: 80.2 ± 12.5 mmHg versus 78.9 ± 15.6, respectively). CONCLUSION: This study confirms the safety of adenosine infusion during cardiac MRI. A considerable proportion of all patients will experience minor adverse effects and some patients will not tolerate adenosine infusion. However, all adverse events can be successfully managed by a radiologist. The increased heart rate during adenosine infusion highlights the need to individually adjust the settings according to the patient, e.g., the number of slices of myocardial perfusion imaging.
Authors: Susan E Langerak; Hubert W Vliegen; Albert de Roos; Aeilko H Zwinderman; J Wouter Jukema; Patrik Kunz; Hildo J Lamb; Ernst E van Der Wall Journal: Circulation Date: 2002-01-22 Impact factor: 29.690
Authors: Matthew J Budoff; Mylan C Cohen; Mario J Garcia; John McB Hodgson; W Gregory Hundley; Joao A C Lima; Warren J Manning; Gerald M Pohost; Paolo M Raggi; George P Rodgers; John A Rumberger; Allen J Taylor; Mark A Creager; John W Hirshfeld; Beverly H Lorell; Geno Merli; George P Rodgers; Cynthia M Tracy; Howard H Weitz Journal: Circulation Date: 2005-07-26 Impact factor: 29.690
Authors: David M Biko; R Thomas Collins; Sara L Partington; Matthew Harris; Kevin K Whitehead; Marc S Keller; Mark A Fogel Journal: Pediatr Cardiol Date: 2017-10-24 Impact factor: 1.655
Authors: Nicole M Bhave; Benjamin H Freed; Chattanong Yodwut; Denise Kolanczyk; Karin Dill; Roberto M Lang; Victor Mor-Avi; Amit R Patel Journal: J Cardiovasc Magn Reson Date: 2012-12-28 Impact factor: 5.364
Authors: Jonathon A Nye; Marina Piccinelli; Doyeon Hwang; Charles David Cooke; Jin Chul Paeng; Joo Myung Lee; Sang-Geon Cho; Russell Folks; Hee-Seung Bom; Bon-Kwon Koo; Ernest V Garcia Journal: Med Phys Date: 2021-07-20 Impact factor: 4.506